sprite-preloader
Anzeige
Mehr »
Sonntag, 20.05.2018 Börsentäglich über 12.000 News von 577 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A115FR ISIN: US9097471075 Ticker-Symbol: N/A 
Aktie:
15.02.2018 | 14:25
(1 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

Patent-Protected Line Includes Active and Non-Active Capsules, Sublinguals, Transdermals, Topicals, Vape Formulations and Infused Water

DENVER, CO / ACCESSWIRE / February 15, 2018 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced that Jamaica's Ministry of Health has approved its entire patent-protected Prana collection for use by registered medicinal cannabis patients.


UNITED CANNABIS CORPORATION

JAMAICAN MINISTRY PRODUCT REGISTRATION

Non-Active Capsules

10,20,50 mg

Active Capsules

10,20,50 mg

Sublingual

400 mg

Transdermal

Topical

Vape Formulation

Water

P1

X

X

X

X

X

X

P2

X

X

X

X

P3

X

X

X

X

X

P4

X

X

X

X

P5

X

X

X

X

X

X


The Prana Collection is the foundation of the Company's cannabis-centric formulations, which patients have found effective in helping manage the symptoms of arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle recovery, migraines, and various skin conditions.

Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement, "The Jamaican market continues to be favorable, on both a regulatory and operational basis, enabling us to diversify out of the United States. Of course, we remain confident that the US market will continue to move toward legalization of medical cannabis, but with our complete line now registered with the Ministry of Health, Jamaica can also serve as a gateway to other open markets. We, along with our partners, are already talking with customers in Canada, Australia, New Zealand, The Philippines and Nigeria."

About Cannabinoid Research & Development Limited

Cannabinoid Research & Development (CRD), a subsidiary of United Cannabis, is a Jamaican based corporation pursuing local licensing to advance the use of medical cannabis therapies through biomedical research and development for the nutraceutical industry. CRD focuses on genetic restoration, cannabinoid isolation techniques, scientific research, educational programs, and promotes domestic job opportunities. John Sayers, along with Kenyama Brown, local Jamaican directors and executives of CRD, coupled with Jamaican partners specializing in agricultural science and plant based medicine, will help United Cannabis implement Sayer's 40 years of agricultural methodologies into localized educational curriculums, job training programs, and help with integration of localized products.

About United Cannabis Corporation

United Cannabis Corporation is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. The Company's products are patent protected first in class medicines with applications to a global market. United Cannabis trades on the OTCQB under the symbol CNAB.

For further information, please visit www.unitedcannabis.us.

Contact: Staff@UnitedCannabis.us

Phone: 303-386-7321

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: United Cannabis Corporation


© 2018 ACCESSWIRE